Thiophosphonoformic acid

Drug Profile

Thiophosphonoformic acid

Alternative Names: ANX-201; Pyrophosphate analogue - ADVENTRX Pharmaceuticals; Thiophosphonoformate; Thiovir; TPFA

Latest Information Update: 30 Oct 2008

Price : $50

At a glance

  • Originator University of Southern California
  • Class Antivirals
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections; HIV infections; Human papillomavirus infections; Influenza virus infections

Most Recent Events

  • 31 Mar 2008 Pharmacodynamics & pharmacokinetic data released by ADVENTRX Pharmaceuticals
  • 23 Jul 2007 Preclinical data added to the Viral Infections antimicrobial activity section ,
  • 07 May 2007 Preclinical data added to the Viral Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top